“In September last year, a Memorandum of Understanding was signed between AstraZeneca’s BioVentureHub and Innovation Agency Lithuania. We are pleased to share that we have now moved from commitment to action and are welcoming Biomatter – the first Lithuanian company into the BioVentureHub. This milestone represents another building block in the bridge we are forming between the life science ecosystems of Lithuania and Sweden,” states Ulrika Edvardsson, Managing Director, AstraZeneca BioVentureHub.

“By connecting Lithuanian innovators with the strong experience of the Nordic pharmaceutical industry, this partnership creates a powerful ‘snowball effect’ – supporting the growth of more high-potential startups, attracting top talent, and building long-term competitiveness,” states Paulius Kamaitis, Acting Director of Innovation Agency Lithuania. 

Biomatter

Through their platform, the company combines physics-based modeling with AI to engineer enzymes from the bottom up. Biomatter partners on end-to-end development to create custom enzymes across industrial biotech, biopharma, and life sciences.

“Joining AstraZeneca BioVentureHub opens doors to a unique R&D ecosystem. By bringing our enzyme platform closer to the AstraZeneca’s industrial expertise, we are building a strong foundation for innovation and the collaborative projects to come,” says Laurynas Karpus, CEO & Co-Founder of Biomatter.

“Biomatter’s strengths in AI-driven protein and enzyme design strongly align with AstraZeneca’s work in genome engineering and CRISPR-based technologies. Through the BioVentureHub collaboration, we look forward to exploring how advanced protein design can support next-generation gene editing and delivery tools and accelerate impactful innovation” states Marcello Maresca, Director Biopharma R&D, AstraZeneca.